Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;18(12):1259-1261.
doi: 10.1080/14787210.2020.1794819. Epub 2020 Aug 1.

The use of IV vitamin C for patients with COVID-19: a case series

Affiliations

The use of IV vitamin C for patients with COVID-19: a case series

Raul Hiedra et al. Expert Rev Anti Infect Ther. 2020 Dec.

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic has affected almost 2.5 million people worldwide with almost 170,000 deaths reported to date. So far, there is scarce evidence for the current treatment options available for COVID-19. Vitamin C has previously been used for treatment of severe sepsis and septic shock. We reviewed the feasibility of using vitamin C in the setting of COVID-19 in a series of patients.

Methods: We sequentially identified a series of patients who were requiring at least 30% of FiO2 or more who received IV vitamin C as part of the COVID-19 treatment and analyzed their demographic and clinical characteristics. We compared inflammatory markers pre and post treatment including D-dimer and ferritin.

Results: We identified a total of 17 patients who received IV vitamin C for COVID-19. The inpatient mortality rate in this series was 12% with 17.6% rates of intubation and mechanical ventilation. We noted a significant decrease in inflammatory markers, including ferritin and D-dimer, and a trend to decreasing FiO2 requirements, after vitamin C administration.

Conclusion: The use of IV vitamin C in patients with moderate to severe COVID-19 disease may be feasible.

Keywords: COVID-19; coronavirus; mortality; sepsis; vitamin C.

PubMed Disclaimer

References

    1. World Health Organization . Coronavirus disease; 2019. (COVID-19): situation report, 93.
    1. Wu Z, McGoogan JM.. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020. February 24;323(13):1239. - PubMed
    1. NIH COVID-19 treatment guidelines. https://covid19treatmentguidelines.nih.gov/accessed [cited 2020 April23]
    1. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clinical Infectious Diseases. 2020. April 27. - PMC - PubMed
    1. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020. March 28:1–34. - PMC - PubMed

MeSH terms